← 483 OBSERVATION EXPLORER

FDA 483 OBSERVATION · #945 OF 1,000 MOST-CITED

Establishment and Implementation of Monitoring Preventive Controls

FDA cited this observation 18 times across 17 firms in recent inspections. Below: how it breaks down by program area and fiscal year, and real examples of how FDA worded it on Form FDA 483.

BY PROGRAM AREA
Veterinary Medicine18
BY FISCAL YEAR
FY20261
FY20252
FY20244
FY20234
FY20222
FY20212
FY20202
FY20191

How FDA worded it — real examples

You did not establish written procedures for monitoring, including adequate frequency for your preventive controls.

American Specialty Food Manufacturing, LLC · New Holland, Pennsylvania · Veterinary Medicine · 2025-11-19

You did not establish written procedures for monitoring, including adequate frequency for your preventive controls.

Zeigler Brothers, Inc. · East Berlin, Pennsylvania · Veterinary Medicine · 2025-08-20

You did not establish written procedures for monitoring, including adequate frequency for your preventive controls.

Pony Express Foods, LLC · Lancaster, Pennsylvania · Veterinary Medicine · 2025-03-12

You did not establish written procedures for and implement monitoring, including adequate frequency for your preventive controls.

Farmers Association · Little Rock, Arkansas · Veterinary Medicine · 2024-08-21

You did not establish written procedures for and implement monitoring, including adequate frequency for your preventive controls.

PSD Partners, LLC · Carey, Ohio · Veterinary Medicine · 2024-07-17

You did not establish written procedures for and implement monitoring, including adequate frequency for your preventive controls.

Kent Nutrition Group, Inc. · Arcade, New York · Veterinary Medicine · 2024-05-23

Related SPEQ references

Where to read the requirements behind this observation area on SPEQ. These are SPEQ's topic and audience pages — not an FDA classification of the citation.

Veterinary industry

Examples are a representative sample of FDA's published inspection observations. SPEQ is not affiliated with the FDA; this is a reference view of public FDA data.

Weekly Briefing

Get the Weekly GxP Briefing

Curated regulatory intelligence — enforcement, recalls, guidance, and quality signals — in one practitioner-grade email each week. Free.

Read a past issue →